1.
Herbert AA, Glaab D, Schreiber R. A Multicenter, Open Label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam, 0.005% in Pediatric Subjects (Ages 2 to 11 Years) with Plaque Psoriasis. J of Skin [Internet]. 2020Sep.2 [cited 2022Jul.5];4(5):s35. Available from: https://www.jofskin.org/index.php/skin/article/view/984